SEP 226330

Drug Profile

SEP 226330

Alternative Names: SEP-0226330; SEP-226330

Latest Information Update: 07 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sunovion Pharmaceuticals
  • Class Antiparkinsonians
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease; Restless legs syndrome

Most Recent Events

  • 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
  • 22 Oct 2009 Preclinical trials in Parkinson's disease in USA (PO)
  • 21 Oct 2009 Pharmacodynamics data from primate studies in Parkinson's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN- 2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top